Related Experiment Video
Updated: Jun 23, 2026

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
Association between plasma osteoprotegerin concentrations and urinary albumin excretion in Type 2 diabetes
1Department of Endocrinology, Wuhan General Hospital of Guangzhou Command, Wuhan, Hubei Province, PR China. guangda64@hotmail.com
Aims:
Osteoprotegerin (OPG) is a recently identified inhibitor of bone resorption. Recent studies indicate that OPG is also associated with endothelial dysfunction in Type 2 diabetes. The aim was to investigate the relationship between plasma OPG levels and urinary albumin excretion (UAE) in Type 2 diabetic patients.
Methods:
This study included 154 newly diagnosed Type 2 diabetic patients and 46 healthy subjects. Plasma OPG and 24-h UAE were measured. High-resolution ultrasound was used to measure flow-mediated (endothelium-dependent arterial) dilation (FMD).
Results:
Compared with the normoalbuminuric subgroup, OPG levels in the microalbuminuric subgroup were significantly higher, and OPG levels in macroalbuminuria subgroup were significantly higher than those in the normoalbuminuria and albuminuria subgroups. Multiple regression analysis showed that only FMD (r = -0.26), C-reactive protein (r = 0.23), fasting blood glucose (r = 0.25), 2-h blood glucose (r = 0.21), HbA(1c) (r = 0.28), UAE (r = 0.27) and retinopathy (r = 0.27) were significant factors associated with OPG. Pearson's correlation analyses showed a positive correlation between OPG and logUAE (r = 0.440) and negative correlations between OPG and FMD (r = -0.284), and between FMD and logUAE (r = -0.602).
Conclusions:
Plasma OPG levels are significantly associated with UAE in Type 2 diabetic patients.
Related Concept Videos
Diabetic Nephropathy
Hyperglycemia
Type II Diabetes II: Pathophysiology
Drug Distribution: Plasma Protein Binding
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type I Diabetes III: Clinical Manifestations